Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

12 trials with published results (46%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 26 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

42%

11 trials in Phase 3/4

Results Transparency

75%

12 of 16 completed with results

Key Signals

12 with results100% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (1)
P 2 (8)
P 3 (10)
P 4 (1)

Trial Status

Completed16
Recruiting4
Unknown4
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT06672978Phase 2Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT05905055Phase 3CompletedPrimary

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

NCT06824129Active Not RecruitingPrimary

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR

NCT05887908Phase 3CompletedPrimary

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

NCT04876131Phase 4RecruitingPrimary

Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children

NCT04979806Phase 3CompletedPrimary

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT05733104Recruiting

A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

NCT04682834UnknownPrimary

Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

NCT05385536Completed

Evaluating UTI Outcomes in at Risk Populations

NCT05826990Phase 2RecruitingPrimary

A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

NCT03630081Phase 3Not Yet RecruitingPrimary

Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT03230838Phase 2CompletedPrimary

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

NCT05674032Unknown

Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis

NCT03788967Phase 3CompletedPrimary

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT05060419Phase 2UnknownPrimary

Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

NCT03293485Phase 3Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

NCT03445195Phase 2CompletedPrimary

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

NCT04076436UnknownPrimary

Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.

NCT02728089Phase 3Completed

Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

NCT01345929Phase 3CompletedPrimary

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Scroll to load more

Research Network

Activity Timeline